Results 111 to 120 of about 9,770,479 (402)

Risk factors for tuberculosis treatment outcomes: a statistical learning-based exploration using the SINAN database with incomplete observations

open access: yesBMC Medical Informatics and Decision Making
Background Understanding early predictors of treatment outcomes allows better outcome prediction and resource allocation for efficient tuberculosis (TB) management.
Nguyen Ky Phat   +4 more
doaj   +1 more source

Evidence That Cytochrome \u3cem\u3eb\u3csub\u3e5\u3c/sub\u3e\u3c/em\u3e Acts as a Redox Donor in CYP17A1 Mediated Androgen Synthesis [PDF]

open access: yes, 2016
Cytochrome P450 17A1 (CYP17A1) is an important drug target for castration resistant prostate cancer. It is a bi-functional enzyme, catalyzing production of glucocorticoid precursors by hydroxylation of pregnene-nucleus, and androgen biosynthesis by a ...
Denisov, Ilia G.   +5 more
core   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

open access: yesMolecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop   +10 more
wiley   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

open access: yesMolecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp   +13 more
wiley   +1 more source

Fixed Eruptions: Drug, food, and what more?

open access: yesClinical Dermatology Review
Fixed drug eruption (FDE) is a common entity encountered in our day-to-day clinical practice. It is a T-cell-dependent pathway with induction of interferon-gamma-producing CD8+ T-cells in the dermis and epidermis.
Prabhakar Mallikarjuna Sangolli   +1 more
doaj   +1 more source

Vemurafenib-associated neutrophilic panniculitis in a patient with metastatic amelanotic melanoma presenting as cancer of unknown primary origin

open access: yesDermatologica Sinica, 2016
The treatment of metastatic melanoma is challenging. BRAF gene mutation is found in 40–60% of melanoma cases, the most common being the V600E mutation.
Yu-Ching Weng   +5 more
doaj   +1 more source

Utilizing Multi-level Classification Techniques to Predict Adverse Drug Effects and Reactions [PDF]

open access: yes, 2019
Multi-class classification models are used to predict categorical response variables with more than two possible outcomes. A collection of multi-class classification techniques such as Multinomial Logistic Regression, Na\ {i}ve Bayes, and Support Vector ...
Puhl, Victoria
core   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Acute generalized exanthematous pustulosis induced by iodinated contrast media: a case report

open access: yesDermatology Reports
Acute generalized exanthematous pustulosis (AGEP) is a rare pustular eruption commonly triggered by drugs. It’s characterized by acute onset of pustules on erythematous-edematous skin and often presents with fever.
Maisa Alfalah   +3 more
doaj   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

open access: yesMolecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy